Greece Infection Control Market - Forecasts from 2020 to 2025
Greece infection control market is estimated to attain a market size of USD96.935 million by the end of 2025. The high prevalence of smoking-related health disorders in Greece is estimated to increase market growth in the forecast period. The surge in the occupancy of medical beds in private hospitals is further providing an opportunity for the market to thrive in the forecast period. There is a presence of smaller outpatient clinics in the rural areas which are in collaboration with bigger public hospitals, hence it becomes easier to access faster emergency treatments, further burgeoning the market demand in these outpatient clinics over the next five years. Furthermore, with investments in pharmaceutical industry in Greece along with the growing number of clinical trials resulting in the development of novel drugs, the market is projected to fuel in the forecast period and in the coming years.
The presence of smoking-related diseases is projected to fuel the market growth in the forecast period with the increasing number of treatment procedures for these diseases.
The leading cause of mortality in Greece is attributed to non-communicable diseases which include cardiovascular diseases, cancer, and chronic respiratory diseases. In the case of cancers, lung cancer is considered as the consequence of smoking in the country. A study revealed a high correlation of lung cancer with excessive smoking, as the maximum number of cancer cases was reported to have a history of smoking. This has further contributed to surging the percentage of deaths from COPD, trachea, bronchus, and lung cancers in the European region. Furthermore, it is estimated that this trend will continue to increase until 2030. Hence, smoking, which is considered to be the ultimate cause for these mortalities in Greece, especially the non-communicable respiratory diseases will continue to cause a significant impact on public health and health expenditure. However, in the case of the prevalence of smoking-related disorders, the market for infection control will continue to surge in the forecast period and in the upcoming years with increasing hospital admissions regarding the diagnosis and treatment of these non-communicable diseases at various disease stages.
The growing investments in the life sciences and pharma industry is further providing an opportunity for the market to thrive in the forecast period.
Greece consist of a well-established research and development and manufacturing facility hence this is providing strong growth potential for life sciences and pharmaceutical industries to thrive in the forecast period and in the upcoming years. The life sciences industry here is augmenting at a fast pace where new startups are rising and various spin-off companies are continuously focused on pursuing international R&D partnerships in order to develop robust, technology-led products, and services, further fueling the market growth in the forecast period and in the upcoming years. Furthermore, the pharma industry in Greece is a major contributor to the country’s economy and is aimed towards local consumption. The Greek research and development infrastructure including the world-renowned research institutes, research teams, and University research groups are further adding to the strong growth of the life sciences industry.
Segmentation:
The presence of smoking-related diseases is projected to fuel the market growth in the forecast period with the increasing number of treatment procedures for these diseases.
The leading cause of mortality in Greece is attributed to non-communicable diseases which include cardiovascular diseases, cancer, and chronic respiratory diseases. In the case of cancers, lung cancer is considered as the consequence of smoking in the country. A study revealed a high correlation of lung cancer with excessive smoking, as the maximum number of cancer cases was reported to have a history of smoking. This has further contributed to surging the percentage of deaths from COPD, trachea, bronchus, and lung cancers in the European region. Furthermore, it is estimated that this trend will continue to increase until 2030. Hence, smoking, which is considered to be the ultimate cause for these mortalities in Greece, especially the non-communicable respiratory diseases will continue to cause a significant impact on public health and health expenditure. However, in the case of the prevalence of smoking-related disorders, the market for infection control will continue to surge in the forecast period and in the upcoming years with increasing hospital admissions regarding the diagnosis and treatment of these non-communicable diseases at various disease stages.
The growing investments in the life sciences and pharma industry is further providing an opportunity for the market to thrive in the forecast period.
Greece consist of a well-established research and development and manufacturing facility hence this is providing strong growth potential for life sciences and pharmaceutical industries to thrive in the forecast period and in the upcoming years. The life sciences industry here is augmenting at a fast pace where new startups are rising and various spin-off companies are continuously focused on pursuing international R&D partnerships in order to develop robust, technology-led products, and services, further fueling the market growth in the forecast period and in the upcoming years. Furthermore, the pharma industry in Greece is a major contributor to the country’s economy and is aimed towards local consumption. The Greek research and development infrastructure including the world-renowned research institutes, research teams, and University research groups are further adding to the strong growth of the life sciences industry.
Segmentation:
- By Product
- Disinfectant
- Sterilization
- Low temperature Sterilization
- Heat Sterilization
- Contract Sterilization
- By End User Industry
- Healthcare
- Food and Beverage
- Chemical
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Porters Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitutes
4.4.5. Competitive Rivalry in the Industry
4.5. Industry Value Chain Analysis
5. GREECE INFECTION CONTROL MARKET ANALYSIS, BY PRODUCT
5.1. Introduction
5.2. Disinfectant
5.3. Sterilization
5.3.1. Low Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. GREECE INFECTION CONTROL MARKET ANALYSIS, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. 3M
8.2. Medtronic
8.3. Sch?lke & Mayr GmbH
8.4. Franke Medical OY
8.5. Tuttnauer
8.6. List is not Exhaustive*
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Porters Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitutes
4.4.5. Competitive Rivalry in the Industry
4.5. Industry Value Chain Analysis
5. GREECE INFECTION CONTROL MARKET ANALYSIS, BY PRODUCT
5.1. Introduction
5.2. Disinfectant
5.3. Sterilization
5.3.1. Low Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. GREECE INFECTION CONTROL MARKET ANALYSIS, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. 3M
8.2. Medtronic
8.3. Sch?lke & Mayr GmbH
8.4. Franke Medical OY
8.5. Tuttnauer
8.6. List is not Exhaustive*
